Delivery Order SPE2DR25D1109-SPE2DR26FFJ6K
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,820.60 to AmerisourceBergen Drug Corp for the supply of INFANRIX DTAP Syringe 0.5ML, a diphtheria, tetanus, and acellular pertussis vaccine. This non-set-aside, competitively awarded contract carries a firm fixed price and is scheduled for completion by June 2, 2025. The vaccine will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a $1,913.65 delivery order to AmerisourceBergen Drug Corp for INFANRIX DTAP vaccine syringes (0.5mL) with a completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide INFANRIX DTAP SYRINGE 0.5ML vaccines. This $1,204.90 contract has a period of performance through April 15, 2024. AmerisourceBergen Drug Corp is the prime contractor for this order, which is a child contract under a potential $999,999,999.00 indefinite delivery contract (IDC) the company holds with DLA to supply...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $2,036.15 to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is for the supply of INFANRIX DTAP SYRINGE 0.5ML, a pediatric vaccine product, with a period of performance through April 10, 2024. Amerisourcebergen Drug Corp holds a larger indefinite delivery contract (IDC) with DLA Troop Support Medical, valued at up to...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $5,641.12 by the Defense Logistics Agency (DLA) on September 18, 2025, with an ultimate completion date of September 19, 2025. The contract, awarded under firm fixed pricing with no set-aside designation, calls for the delivery of Pediarix 0.5 mL syringes. This delivery order represents a single purchase transaction under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a $5,072.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5ML) on December 2, 2025, with completion scheduled for December 3, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The vaccine will be delivered to the...
- The Defense Logistics Agency awarded a $144,730 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 4562195770 INFANRIX DTAP SYRINGE 0.5ML. As the prime contractor, Amerisourcebergen will deliver the diphtheria, tetanus, and pertussis vaccine syringes to support DLA's medical supply needs. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a three day period concluding on September 18, 2023. No subcontractors or set aside...
- This contract award to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation, is for the delivery of DAPTACEL DTAP vaccine in 0.5mL doses. The $1,159.16 firm fixed price delivery order was issued by the Defense Logistics Agency (DLA) Troop Support Medical division and has a completion date of February 12, 2024. Amerisourcebergen Drug Corp, located in Conshohocken, Pennsylvania, is the prime contractor on this delivery order, which does not...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Boostrix TDAP vaccine in 0.5mL syringes. This competitively awarded, non-set-aside contract has a ceiling value of $85,547.20 under a firm fixed price arrangement, with an ultimate completion date of September 16, 2025. The vaccine will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 17, 2025, for $1,415.04 to supply Boostrix TDAP vaccine in 0.5mL syringes. This is a firm fixed price delivery order with an ultimate completion date of December 18, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award uses no set-aside designation and...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFJ6KDelivery Order
The Defense Logistics Agency awarded a $1,918.05 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 26, 2025, for the supply of INFANRIX DTAP Syringe 0.5ML, a pediatric diphtheria, tetanus, and pertussis vaccine. The contract is not set-aside and carries an ultimate completion date of December 29, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania. This award represents a child order under the company's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company holds extensive federal contract awards with the Defense Logistics Agency for a comprehensive range of pharmaceutical products, vaccines, and medical supplies across multiple therapeutic domains. All of the company's reviewed contract awards have been competitively awarded with firm fixed pricing structures, demonstrating its capability to fulfill federal medical supply requirements through open competition. The DLA is currently planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, with AmerisourceBergen positioned to continue serving customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 12/25/25 |